News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CSL Biotherapies Contracts with U.S. Department of Health and Human Services to Provide Novel A (H1N1) Influenza Vaccine Antigen


5/29/2009 8:40:50 AM

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--CSL Biotherapies, Inc. announced today that it has signed a contract with the U.S. Department of Health and Human Services (HHS) to provide Novel A (H1N1) influenza vaccine antigen in bulk form to support HHS’ pandemic influenza preparedness efforts. The initial order under contract will be for an amount of at least $180 million. CSL Biotherapies anticipates initial delivery of the antigen by September, subject to regulatory approval. The new vaccine antigen will be tested in clinical trials funded by HHS.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES